$337M | ||
$259M | ||
$76M | ||
$60M | ||
$57M | ||
$50M |
Buys | $79,042,965 | 4 | 14 |
Sells | $342,728,126 | 25 | 86 |
RA CAPITAL MANAGEMENT, L.P. | 4 | $79.04M | 0 | $0 | $79.04M | |
DiRaimondo Thomas | Chief Scientific Officer | 0 | $0 | 1 | $231,716 | $-231,716 |
Meyer Andrew Hollman | Chief Business Officer | 0 | $0 | 4 | $3.28M | $-3.28M |
Campbell David Alan | President and CEO | 0 | $0 | 6 | $6.5M | $-6.5M |
Reardon Tighe | Acting Chief Financial Officer | 0 | $0 | 1 | $45.04M | $-45.04M |
Lichter Jay | 0 | $0 | 2 | $82.3M | $-82.3M | |
Avalon Ventures XI, L.P. | 10 percent owner | 0 | $0 | 11 | $205.38M | $-205.38M |
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against …
Over the last 12 months, insiders at Janux Therapeutics, Inc. have bought $79.04M and sold $342.73M worth of Janux Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Janux Therapeutics, Inc. have bought $69.09M and sold $181.95M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $79.04M.
The last purchase of 110,206 shares for transaction amount of $3.42M was made by RA CAPITAL MANAGEMENT, L.P. () on 2025‑03‑07.
2025-03-07 | RA CAPITAL MANAGEMENT, L.P. | 110,206 0.187% | $31.02 | $3.42M | -1.38% | |||
2025-03-06 | RA CAPITAL MANAGEMENT, L.P. | 372,093 0.6366% | $30.78 | $11.45M | -1.94% | |||
2025-03-05 | RA CAPITAL MANAGEMENT, L.P. | 341,742 0.5742% | $30.64 | $10.47M | -4.16% | |||
2025-03-03 | Sale | Meyer Andrew Hollman | Chief Business Officer | 3,334 0.0059% | $32.15 | $107,174 | -5.15% | |
2025-02-03 | Sale | Meyer Andrew Hollman | Chief Business Officer | 3,334 0.0056% | $42.29 | $140,999 | -25.11% | |
2025-01-07 | Sale | Campbell David Alan | President and CEO | 5,000 0.009% | $60.00 | $300,004 | -41.91% | |
2025-01-02 | Sale | Meyer Andrew Hollman | Chief Business Officer | 13,334 0.0234% | $54.88 | $731,785 | -32.21% | |
2024-12-24 | Sale | Campbell David Alan | President and CEO | 25,000 0.0433% | $56.19 | $1.4M | -34.20% | |
2024-12-03 | Sale | Campbell David Alan | President and CEO | 15,000 0.0317% | $67.00 | $1M | -32.52% | |
2024-11-25 | Sale | Campbell David Alan | President and CEO | 25,000 0.0505% | $51.60 | $1.29M | -16.67% | |
2024-10-28 | Sale | Campbell David Alan | President and CEO | 25,000 0.0486% | $53.54 | $1.34M | -18.86% | |
2024-10-18 | Sale | Avalon Ventures XI, L.P. | 10 percent owner | 1.46M 2.5633% | $45.76 | $66.9M | -10.47% | |
2024-10-18 | RA CAPITAL MANAGEMENT, L.P. | 1.2M 2.0576% | $44.75 | $53.7M | -10.47% | |||
2024-10-17 | Sale | Avalon Ventures XI, L.P. | 10 percent owner | 1,843 0.0035% | $50.02 | $92,187 | -9.81% | |
2024-10-16 | Sale | Avalon Ventures XI, L.P. | 10 percent owner | 209,516 0.4311% | $50.03 | $10.48M | -8.80% | |
2024-09-30 | Sale | Avalon Ventures XI, L.P. | 10 percent owner | 958 0.0018% | $46.24 | $44,298 | -0.81% | |
2024-09-27 | Sale | Campbell David Alan | President and CEO | 25,000 0.0476% | $46.31 | $1.16M | -2.41% | |
2024-09-27 | Sale | DiRaimondo Thomas | Chief Scientific Officer | 5,000 0.0095% | $46.34 | $231,716 | -2.41% | |
2024-09-27 | Sale | Meyer Andrew Hollman | Chief Business Officer | 50,000 0.0945% | $45.96 | $2.3M | -2.41% | |
2024-09-27 | Sale | Avalon Ventures XI, L.P. | 10 percent owner | 106,821 0.2041% | $46.46 | $4.96M | -2.41% |
RA CAPITAL MANAGEMENT, L.P. | 10141287 17.158% | $247.24M | 6 | 0 | <0.0001% | |
Reardon Tighe | Acting Chief Financial Officer | 633673 1.0721% | $15.45M | 2 | 1 | +247.14% |
Avalon Ventures XI, L.P. | 10 percent owner | 401321 0.679% | $9.78M | 2 | 11 | +247.14% |
Lichter Jay | 10 percent owner | 7000 0.0118% | $170,660.00 | 2 | 2 | +247.14% |
Bregua Corp | 10 percent owner | 3749250 6.3434% | $91.41M | 1 | 0 | +1.61% |
ORBIMED ADVISORS LLC | director | 231098 0.391% | $5.63M | 1 | 3 | +1.61% |
Thompson Peter A. | director | 231098 0.391% | $5.63M | 1 | 3 | +1.61% |
$831,902,292 | 108 | 9.34% | $1.43B | |
$20,297,544 | 73 | 103.06% | $1.42B | |
$11,583,737 | 45 | 49.75% | $1.35B | |
$148,770,544 | 34 | 80.63% | $1.27B | |
$150,253,463 | 26 | -52.83% | $1.5B |
Increased Positions | 159 | +116.06% | 21M | +46.04% |
Decreased Positions | 61 | -44.53% | 2M | -4.41% |
New Positions | 79 | New | 6M | New |
Sold Out Positions | 22 | Sold Out | 969,051 | Sold Out |
Total Postitions | 235 | +71.53% | 64M | +41.63% |
Ra Capital Management, L.P. | $298,531.00 | 17.57% | 10.37M | +1M | +13.09% | 2024-12-31 |
Fmr Llc | $249,694.00 | 14.7% | 8.67M | +845,266 | +10.8% | 2024-12-31 |
Janus Henderson Group Plc | $102,597.00 | 6.04% | 3.56M | +1M | +41.17% | 2024-12-31 |
Paradigm Biocapital Advisors Lp | $101,260.00 | 5.96% | 3.52M | +1M | +46.46% | 2024-12-31 |
Adage Capital Partners Gp, L.L.C. | $88,178.00 | 5.19% | 3.06M | +986,750 | +47.55% | 2024-12-31 |
Blackrock, Inc. | $78,503.00 | 4.62% | 2.73M | +303,177 | +12.51% | 2024-12-31 |
Vanguard Group Inc | $61,526.00 | 3.62% | 2.14M | +288,402 | +15.61% | 2024-12-31 |
Cormorant Asset Management, Lp | $60,480.00 | 3.56% | 2.1M | +1M | New | 2024-12-31 |
Woodline Partners Lp | $53,343.00 | 3.14% | 1.85M | +251,924 | +15.74% | 2024-12-31 |
Ecor1 Capital, Llc | $42,331.00 | 2.49% | 1.47M | 0 | 0% | 2024-12-31 |